Vaccine Clinical Trial
— PVIOfficial title:
Physician-Pharmacy Collaboration to Increase Patient Acceptance of Pneumococcal Immunization Prior to Inpatient Discharge
NCT number | NCT06136832 |
Other study ID # | 2023-1678 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | May 6, 2024 |
Est. completion date | June 1, 2025 |
The goal of this interventional clinical trial is to investigate the impact of medicine and pharmacy-led education on patient acceptance rates of Prevnar 20 pneumonia vaccination in patients eligible to receive the vaccine. The education intervention and subsequent option to get the vaccine will be done while the patient is admitted to inpatient care, prior to discharge. The main questions the study aims to answer are: - Will supplemental education about the Prevnar 20 Pneumococcal vaccine influence patient acceptance rates when given a decision to receive it? - Is there any other statistically relevant qualitative reasoning behind the patient's final decision for accepting or refusing the vaccine?
Status | Recruiting |
Enrollment | 100 |
Est. completion date | June 1, 2025 |
Est. primary completion date | June 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 64 Years |
Eligibility | Inclusion Criteria: - Patients admitted to inpatient Family Medicine service with Type I and II Diabetes. - Patients who have not been previously vaccinated against pneumonia. - Patients meeting specific eligibility for Prevnar 20 vaccine: Over age of 65 OR have been diagnosed with any of the following: diabetes, chronic obstructive pulmonary disease, or asthma. Exclusion Criteria: - Patients that already received pneumonia vaccination in care history. - Patients with pneumonia inpatient diagnosis at time of recruitment. - Patients with any active infections. - Patients who are in an immunosuppressed status. - Patients allergic to any components of the vaccine. |
Country | Name | City | State |
---|---|---|---|
United States | Geisinger South Wilkes-Barre | Wilkes-Barre | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Geisinger Clinic |
United States,
Ahmad Hamidi A, Gelmez Tas B, Gunduz A, Nur Celebi S, Esen ES, Toprak D, Dokmetas I. Immunization rates of pneumococcal, influenza and tetanus vaccines and knowledge and attitudes of adult patients who receive inpatient treatment at hospital: Point prevalence study. Hum Vaccin Immunother. 2018;14(11):2649-2653. doi: 10.1080/21645515.2018.1489187. Epub 2018 Jul 12. — View Citation
Cotugno S, Morrow G, Cooper C, Cabie M, Cohn S. Impact of pharmacist intervention on influenza vaccine assessment and documentation in hospitalized psychiatric patients. Am J Health Syst Pharm. 2017 Dec 1;74(23 Supplement 4):S90-S94. doi: 10.2146/ajhp160755. — View Citation
Coyle CM, Currie BP. Improving the rates of inpatient pneumococcal vaccination: impact of standing orders versus computerized reminders to physicians. Infect Control Hosp Epidemiol. 2004 Nov;25(11):904-7. doi: 10.1086/502317. — View Citation
Dodds ES, Drew RH, May DB, et al. Impact of a Pharmacy Student-Based Inpatient Pneumococcal Vaccination Program. AJPE 2001;65.
McFadden K, Seale H. A review of hospital-based interventions to improve inpatient influenza vaccination uptake for high-risk adults. Vaccine. 2021 Jan 22;39(4):658-666. doi: 10.1016/j.vaccine.2020.12.042. Epub 2020 Dec 21. — View Citation
Queeno BV. Evaluation of Inpatient Influenza and Pneumococcal Vaccination Acceptance Rates With Pharmacist Education. J Pharm Pract. 2017 Apr;30(2):202-208. doi: 10.1177/0897190016628963. Epub 2016 Jul 9. — View Citation
Rees S, Stevens L, Drayton J, Engledow N, Sanders J. Improving inpatient pneumococcal and influenza vaccination rates. J Nurs Care Qual. 2011 Oct-Dec;26(4):358-63. doi: 10.1097/NCQ.0b013e31821fb6bb. — View Citation
Robke JT, Woods M. A decade of experience with an inpatient pneumococcal vaccination program. Am J Health Syst Pharm. 2010 Jan 15;67(2):148-52. doi: 10.2146/ajhp080638. — View Citation
Stinchfield PK. Practice-proven interventions to increase vaccination rates and broaden the immunization season. Am J Med. 2008 Jul;121(7 Suppl 2):S11-21. doi: 10.1016/j.amjmed.2008.05.003. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of patients accepting the Prevnar 20 Pneumococcal vaccine after receiving pharmacy-led education intervention during standard care. | Patients answering "yes" when given the option to receive the Prevnar 20 Pneumococcal vaccine after they receive vaccine-specific education to increase their knowledge and awareness of the pneumonia vaccine. | Through study completion of up to one year. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04460235 -
Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma
|
Phase 4 | |
Recruiting |
NCT04543877 -
WHNRC (Western Human Nutrition Research Center) Fiber Intervention Study
|
Early Phase 1 | |
Completed |
NCT00401505 -
Rubella Susceptibility in Multiparous Women
|
||
Recruiting |
NCT05054621 -
Immunogenicity of COVID-19 Vaccine on Heterologous Schedule
|
Phase 2 | |
Completed |
NCT05083065 -
Evaluation of Menstrual Irregularities and Abnormal Uterine Bleeding After Covid-19 Vaccine
|
||
Recruiting |
NCT05085145 -
Immunogenicity and Safety of COVID-19 Vaccine in People Living With HIV
|
Phase 4 | |
Completed |
NCT05046548 -
This is a Double-blind, Placebo-controlled, Randomized Study of the Tolerability, Safety and Immunogenicity of an Inactivated Whole Virion Concentrated Purified Vaccine (CoviVac) Against Covid-19
|
Phase 1/Phase 2 | |
Completed |
NCT01961947 -
Study of ASP7374, Cell-culture-derived Influenza Vaccine
|
Phase 3 | |
Completed |
NCT01961960 -
A Study to Evaluate Intramuscular ASP7374
|
Phase 3 | |
Completed |
NCT00401700 -
Influenza Vaccine Postpartum Questionnaire
|
||
Completed |
NCT03300050 -
Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine
|
Phase 1 | |
Completed |
NCT01015703 -
Open-label Safety and Tolerability Study of CoVaccine HTâ„¢ in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00560066 -
Safety of a Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs in Adults and Elderly With and Without Underlying Medical Conditions, and Immunogenicity in a Subset of Subjects With Underlying Medical Conditions
|
Phase 4 | |
Active, not recruiting |
NCT05099965 -
Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®)
|
Phase 2 | |
Recruiting |
NCT04638985 -
Evaluation of Immunogenicity and Safety of Combined Immunization of sIPV, DTaP and MMR
|
Phase 4 | |
Active, not recruiting |
NCT04741828 -
Persistence and Long-Term Protection of Vi Antibodies Induced by Vi-DT Conjugate Vaccines in Indonesian
|
Phase 2/Phase 3 | |
Completed |
NCT05083039 -
Observational Program, Study the Preventive Efficacy of the BiVac Polio Vaccine Against the Incidence of Acute Respiratory Infections, Including COVID-19
|
||
Completed |
NCT03714737 -
Immunogenicity and Safety of Bivalent Meningococcal Serogroups A and C Tetanus Toxoid Conjugate Vaccine in Chinese
|
Phase 3 | |
Completed |
NCT04664309 -
Understanding Immunity to the COVID-19 Vaccines
|
||
Completed |
NCT06450379 -
Impact of Vaccines on Antimicrobial Microbial Resistance
|